Organogenesis Holdings (ORGO) Gains from Investment Securities (2018 - 2026)

Organogenesis Holdings' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 38.44% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 271.94% YoY), while the FY2025 annual figure was $12.0 million, up 13.26% from the prior year.
• Gains from Investment Securities was $1.1 million for Q1 2026 at Organogenesis Holdings, up from $302000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $12.0 million in Q2 2025 to a low of -$2.3 million in Q4 2024.
• Historically, Gains from Investment Securities has averaged $1.9 million across 5 years, with a median of $1.6 million in 2025.
• Biggest YoY gain for Gains from Investment Securities was 693.4% in 2022; the steepest drop was 166.25% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at -$1.7 million in 2022, then gained by 1.41% to -$1.7 million in 2023, then tumbled by 39.01% to -$2.3 million in 2024, then surged by 112.9% to $302000.0 in 2025, then surged by 266.08% to $1.1 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.1 million (Q1 2026), $302000.0 (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.